In AML, c-JUN overexpression has rescued defective antigen receptor signaling and enhance antileukemic activity; notably, this approach is currently being evaluated in a phase I clinical trial of CD33-directed CAR T cells [113] (NCT04835519). Here, CD33 is linked to acute myeloid leukemia.